Intranasal LAG3 antibody infusion induces a rapid antidepressant effect via the hippocampal ERK1/2-BDNF signaling pathway in chronically stressed mice DOI

Yunli Fang,

Hainan Pan,

Hao‐Jie Zhu

et al.

Neuropharmacology, Journal Year: 2024, Volume and Issue: 259, P. 110118 - 110118

Published: Aug. 15, 2024

Language: Английский

Lipoplexes’ Structure, Preparation, and Role in Managing Different Diseases DOI
Sally A. El‐Zahaby, Lovepreet Kaur, Ankur Sharma

et al.

AAPS PharmSciTech, Journal Year: 2024, Volume and Issue: 25(5)

Published: June 7, 2024

Language: Английский

Citations

5
Redefining Hepatocellular Carcinoma Treatment: Nanotechnology Meets Tumor Immune Microenvironment DOI
Chen Mi, Sai Liu, Zhida Chen

et al.

Journal of drug targeting, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 47

Published: March 13, 2025

Hepatocellular carcinoma (HCC) is one of the most lethal malignancies worldwide, characterized by its complex pathogenesis and poor therapeutic outcomes. Despite recent advances in targeted molecular therapies, immune checkpoint inhibitors (ICIs), radiotherapy, conventional chemotherapy, five-year survival rate for this neoplasm remains dismally low. The progress nanotechnology has revolutionized cancer treatment years. These provide unprecedented opportunities to overcome current limitations different modalities. This review provides a comprehensive analysis how interfaces with tumor microenvironment (TIME) HCC can present new frontier interventions HCC. We critically overview latest developments nanoparticle-based delivery systems various drugs also other antitumor agents like thermal therapy radiotherapy. highlight unique ability nanoparticles modulate immunosuppressive (TME) enhance efficacy. Furthermore, we analyze emerging strategies that exploit nanoformulations biological barriers drug bioavailability treatment.

Language: Английский

Citations

0
Advancements and challenges in personalized neoantigen-based cancer vaccines DOI Creative Commons

Parminder Singh,

Mahalaqua Nazli Khatib,

R Roopashree

et al.

Oncology Reviews, Journal Year: 2025, Volume and Issue: 19

Published: March 14, 2025

Advancements in personalized neoantigen-based cancer vaccines are ushering a new era oncology, targeting unique genetic alterations within tumors to enhance treatment precision and efficacy. Neoantigens, specific cells absent normal tissues, at the heart of these vaccines, promising direct immune system specifically against tumor, thereby maximizing therapeutic efficacy while minimizing side effects. The identification neoantigens through genomic proteomic technologies is central developing allowing for precise mapping tumor's mutational landscape. Despite advancements, accurately predicting which will elicit strong responses remains challenging due tumor variability complexity interactions. This necessitates further refinement bioinformatics tools predictive models. Moreover, heavily depends on innovative delivery methods that neoantigen presentation system. Techniques like encapsulating lipid nanoparticles using viral vectors critical improving vaccine stability delivery. Additionally, contribute towards achieving Sustainable Development Goal 3.8, promoting universal health coverage by advancing access safe effective treatments. review delves into potential transform treatment, examining both revolutionary advancements ongoing challenges they face.

Language: Английский

Citations

0
Vaccination and personalized cancer vaccines focusing on common cancers in women: a narrative review DOI
Seyed Sadeq Mousavi Ghahfarrokhi, Pegah Karimi,

Fateme-Sadat Mahdigholi

et al.

Pathology - Research and Practice, Journal Year: 2025, Volume and Issue: 270, P. 155983 - 155983

Published: April 18, 2025

Language: Английский

Citations

0
Harnessing Histone Deacetylase Inhibitors for Enhanced Cancer Immunotherapy DOI

Fatemeh Hedayat,

Elnaz Faghfuri

European Journal of Pharmacology, Journal Year: 2025, Volume and Issue: 997, P. 177620 - 177620

Published: April 14, 2025

Language: Английский

Citations

0
Approaches and challenges in cancer immunotherapy pathways DOI Open Access
Μαρία Καπρίτσου

World Journal of Clinical Oncology, Journal Year: 2024, Volume and Issue: 15(3), P. 378 - 380

Published: March 22, 2024

Cancer immunotherapy is an effective with critical approaches in the treatment of oncological patients. Whilst numerous research and clinical trials are underway to develop endogenous approaches, it necessary focus on fundamental issues identify barriers basic progress. Addressing these challenges new pathways will require researchers clinicians join forces accelerate understanding complex interactions between cancer immune system resources developing better treatments for

Language: Английский

Citations

0
Immunoadjuvants in Cancer Immunotherapy DOI

Mamta N. Talati,

Neeraj Kumar Chouhan,

Mani Sharma

et al.

Advances in medical diagnosis, treatment, and care (AMDTC) book series, Journal Year: 2024, Volume and Issue: unknown, P. 311 - 350

Published: Aug. 28, 2024

Immunoadjuvants are crucial components of cancer immunotherapy that enhance immune responses against tumors. This chapter explores the underlying mechanisms and clinical uses immunoadjuvants in immunotherapy. Toll-like receptor agonists STING two types activate cells promote anti-tumor immunity. Cytokine-based have potential toxicity off-target effects, but nanotechnology enables precision delivery to minimize these issues. Personalized approaches, biomarker discovery, predictive modeling important for optimizing treatment responses. Overall, essential tools generating strong long-lasting In conclusion, critical immunotherapy, playing a vital role boosting durable

Language: Английский

Citations

0
Intranasal LAG3 antibody infusion induces a rapid antidepressant effect via the hippocampal ERK1/2-BDNF signaling pathway in chronically stressed mice DOI

Yunli Fang,

Hainan Pan,

Hao‐Jie Zhu

et al.

Neuropharmacology, Journal Year: 2024, Volume and Issue: 259, P. 110118 - 110118

Published: Aug. 15, 2024

Language: Английский

Citations

0